On March 29, 2020, AbCellera Biologics, Inc., a biopharmaceutical company based in San Diego, California, announced that it has entered into a multi-year agreement to acquire a second antibody for the treatment of COVID-19. The deal is subject to approval by the U.S. Food and Drug Administration (FDA) and the European Commission (E.D.A.D.A.D.A.). The deal is subject to approval by the FDA. The deal is subject to approval by the E.D.A.D.A., the European Commission, and the U.S. Department of Health and Human Services. The deal is subject to regulatory approval. The deal is subject to approval by the Commission. The company has agreed to the entry of a final judgment that permanently enjoins it from violating the antifungal registration provisions of the federal securities laws. The settlement is subject to approval by the Commission. The Commission also agreed to pay a civil penalty of $2.6 million. The Commission's investigation was conducted by Natalie Booth and was supervised by C.J. Kerstetter. The Commission appreciates the assistance of the U.S. Attorney's Office for the District of California, the Federal Bureau of Investigation, and the U.S. Postal Inspection Service.